missing translation for 'onlineSavingsMsg'
Learn More
  1. Home
  2. Products
  3. Antibodies
  4. Primary Antibodies
  5. All Primary Antibodies
  6. Invitrogen™ Bemarituzumab Recombinant Monoclonal Antibody
  7. 30283482

Invitrogen™ Bemarituzumab Recombinant Monoclonal Antibody
GREENER_CHOICE

Recombinant Monoclonal Antibody

Brand:  Invitrogen™ MA558313

 View more versions of this product

Product Code. 30283482

  • € 477.00 / 100µg

Please to purchase this item. Need a web account? Register with us today!

This item is not returnable. View return policy

Description

Description

For reconstitution, add sterile, distilled water to achieve a final antibody concentration of 1 mg/mL. Gently shake to solubilize the protein completely. Do not vortex. Reconstituted products should be stored at -80 °.

Bemarituzumab is a subtype-selective humanized monoclonal antibody against FGFR2b. The FIGH study aims to evaluate the efficacy of its combined chemotherapy for untreated advanced gastric cancer or gastroesophageal junction cancer.
TRUSTED_SUSTAINABILITY
Specifications

Specifications

Bemarituzumab
Recombinant Monoclonal
Unconjugated
FPA114-A; FPA-144
Protein A
RUO
Human
Antibody
IgG1
ELISA, Flow Cytometry, Functional Assay, Surface Plasmon Resonance
1 mg/mL
25mM Histidine with 8% sucrose, 0.01% Tween 80 and no preservative; pH 6.2
Human
100 μg
Primary
-20°C, Avoid Freeze/Thaw Cycles
Lyophilized
Product Suggestions

Product Suggestions

Videos
SDS
Documents

Documents

Certificates
Promotions

Promotions

Product Content Correction

Your input is important to us. Please complete this form to provide feedback related to the content on this product.

Product Title

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.

Thank You! Your feedback has been submitted. Fisher Scientific is always working to improve our content for you. We appreciate your feedback.